Das Städtische Krankenhaus Am Friedrichshain war das erste städtische Krankenhaus Berlins. 1874 eingeweiht, befindet es sich in Berlin-Friedrichshain, an der Landsberger Allee am Rande des Volksparks Friedrichshain.

During the past decade, Vivantes Klinikum im Friedrichshain conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 12 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 5 clinical trials were completed. i.e. 55.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vivantes Klinikum im Friedrichshain" #1 sponsor was "Baxalta now part of Shire" with 7 trials, followed by "Pfizer" with 5 trials sponsored, "Charite University, Berlin, Germany" with 3 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored and "Bürgerhospital Frankfurt" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vivantes Klinikum im Friedrichshain" #1 collaborator was "Abbott" with 2 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "BARMER" with 1 trials as a collaborator and "Boston Scientific Corporation" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Vivantes Klinikum im Friedrichshain" are "Hemophilia A" (8 trials), "Hemophilia B" (6 trials), "Coronary Artery Disease" (4 trials), "Heart Failure" (2 trials) and "Ischemic Heart Disease" (2 trials). Many other conditions were trialed in "Vivantes Klinikum im Friedrichshain" in a lesser frequency.

Most popular intervention types in "Vivantes Klinikum im Friedrichshain" are "Drug" (15 trials), "Device" (11 trials), "Biological" (9 trials), "Other" (4 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Prehabilitation- new form of care" (2 trials), "AAV5-hFIX" (1 trials), "AAV5-hFIXco-Padua" (1 trials) and "Abciximab + UFH" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vivantes Klinikum im Friedrichshain" are 30 trials for "All" genders, 9 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are 14 active trials in "Vivantes Klinikum im Friedrichshain". 2 are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 24 completed trials in Vivantes Klinikum im Friedrichshain, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Vivantes Klinikum im Friedrichshain, 3 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".